Health Business Week
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Health Business Week
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Alkermes, Inc.
FDA Grants Approval for Use of RISPERDAL® CONSTA® as Both a Monotherapy and Adjunctive Therapy in the Maintenance Treatment of Bipolar I Disorder
June 5th, 2009
Alkermes, Inc. (NASDAQ: ALKS) announced that Johnson & Johnson Pharmaceutical Research & Development, L.L.C. (J&JPRD) has received approval from the U.S. Food and Drug Administration (FDA) for the use of RISPERDAL® CONSTA® (risperidone) Long-Acting Injection as both a monotherapy and adjunctive therapy to lithium or valproate in the maintenance treatment of bipolar I disorder. Bipolar disorder is a brain disorder that causes unusual shifts in a person's mood, energy and ability to function. It is often characterized by debilitating mood swings from extreme highs (mania) to extreme lows (depression). Type I bipolar disorder is characterized based on the occurrence of at...
Source: Health Business Week (2009-06-05)
|
